Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.56 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.55 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.55 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.55 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.52 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 4/20 | 0.56 |
| ▸ | DRD3 | P35462 | 3/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL7529655 | 1.00 | DRD2 (0.56) | DRD2HTR1ADRD3DRD4HTR2A | |
| SCHEMBL5185914 | 0.91 | HTR1A (0.56) | DRD2HTR1ADRD3DRD4HTR2A | |
| Fumaric Acid SCHEMBL7528638 | 0.89 | HTR1A (0.56) | DRD2HTR1ADRD3DRD4HTR2A | |
| Fumaric Acid SCHEMBL7528644 | 0.89 | HTR1A (0.56) | DRD2HTR1ADRD3DRD4HTR2A | |
| Fumaric Acid SCHEMBL7520762 | 0.87 | HTR1A (0.55) | DRD2HTR1ADRD3DRD4HTR2A | |
| Fumaric Acid SCHEMBL7520755 | 0.87 | HTR1A (0.55) | DRD2HTR1ADRD3DRD4HTR2A | |
| Fumaric Acid SCHEMBL7528564 | 0.86 | MEN1 (0.49) | DRD2HTR1ADRD3DRD4HTR2A | |
| Fumaric Acid SCHEMBL7519064 | 0.86 | MEN1 (0.49) | DRD2HTR1ADRD3DRD4HTR2A | |
| Fumaric Acid SCHEMBL7528566 | 0.86 | MEN1 (0.49) | DRD2HTR1ADRD3DRD4HTR2A | |
| Fumaric Acid SCHEMBL7519061 | 0.86 | MEN1 (0.49) | DRD2HTR1ADRD3DRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-05-16 | — | — | US | claimed |
| US-6432958-B1 | FOR THERAPY AND PROPHYLAXIS OF NEUROPSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA, MANIA, DEMENTIA, DEPRESSION, ANXIETY, COMPULSIVE BEHAVIOR, SUBSTANCE ABUSE, MOTOR DISORDERS AND MOTION DISORDERS RELATED TO USE OF NEUROLEPTIC AGENT | NEUROGEN CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-05-16 | — | — | US | disclosed |
| US-6284759-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | CHRNA7, HTR7, OPRD1 | DRD2 8/4885HTR2A 45/4885SLC6A4 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.